Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-12-11
Court District Court, D. Delaware Date Terminated 2010-07-13
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand None Referred To
Patents 6,316,460; 6,589,959; 6,858,618
Attorneys Charles E. Lipsey; Colleen Tracy; Daniel V. Folt; Darren Scott Mogil; Edward V. Di Lello; Ford F. Farabow; George H. Seitz , III; Henry J. Renk; John D. Livingstone; Kenneth M. Frankel; Martin B. Pavane; Mary K. Ferguson; Mary W. Bourke; Richard William Riley; York M. Faulkner
Firms Duane Morris, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca Pharmaceuticals LP v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2008-01-31 12 Answer to Complaint ‘3 14 patent is invalid and unenforceable, and that U.S. Patent No. 6,316,460 (“the ‘460 patent”), U.S….S. Patent No. 6,858,618 (“the ‘61 8 patent”) and U.S. Patent No. 6,589,959 (“the ‘959 patent”) are invalid…belief that the ‘314 patent, the ‘460 patent, the ‘618 patent, and the ‘959 patent were invalid, unenforceable… to enforce the ‘314 patent, the ‘460 patent, the ‘618 patent and the ‘959 patent First Counterclaim-… that U.S. Patent No. RE37,314 (“the 314 patent”) was reissued by the United States Patent and Trademark External link to document
2008-03-28 23 Redacted Document 6,858,618 (‘;the ‘618 patent”), and 6,589,959 (“the ‘959 patent”). The ‘460 and ‘618 patents are listed in “…noninfringement of three patents not asserted by AstraZeneca-U.S. Patent Nos. 6,316,460 (“the ‘460 patent”), 6,858,618…Related to the ‘959 Patent Cannot Lie Unlike the ‘460 and ‘618 patents, the ‘959 patent is not listed in… for infringement of U.S. Reissue Patent RE37,314 (“the ‘3 14 patent”) under 35 U.S.C. § 271(e)(2)(A) …challenge the ‘3 14 patent In an effort to resolve the multiple challenges to its patent rights, AstraZeneca External link to document
2008-05-21 39 Stipulation of Dismissal FOR RELIEF RELATING TO U.S. PATENT NOS. 6,316,460; 6,858,618; AND 6,589,959 by AstraZeneca Pharmaceuticals…RELATING TO U.S. PATENT NOS. 6,316,460; 6,858,618; AND 6,589,959 IT IS HEREBY STIPULATED…for Relief relating to U.S. Patent Nos. 6,316,460; 6,858,618; and 6,589,959 in Answer, Affirmative Defenses…2007 13 July 2010 1:07-cv-00807-JJF Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.